CytoSorbents Devices Wins Emergency Approval to Treat COVID-19 Patients
- The Food and Drug Administration says it granted Emergency Use Authorization for CytoSorbent’s (NASDAQ:CTSO) CytoSorb device to treat patients with confirmed Covid-19 admitted to the ICU with confirmed or imminent respiratory failure.
- Based on bench performance testing and reported clinical experience, the FDA concludes the CytoSorb device – also referred to as an Extracorporeal Blood Purification device – may be effective at treating certain patients with confirmed Covid-19 by removing various pro-inflammatory cytokines from their blood.
- The FDA believes the removal of pro-inflammatory cytokines may ameliorate cytokine storm due to the overabundance of pro-inflammatory cytokines and thus provide clinical benefit.
